Lupus Nephritis Treatments
Find Lupus Nephritis Treatments
Brand Name
Saphnelo
Generic Name
Anifrolumab-fnia
View Brand Information FDA approval date: July 30, 2021
Classification: Type I Interferon Receptor Antagonist
Form: Injection
What is Saphnelo (Anifrolumab-fnia)?
SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus , who are receiving standard therapy. Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. SAPHNELO is a type I interferon receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus , who are receiving standard therapy. Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment